• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients.

作者信息

Pesko Bryan, Deng Alexandra, Chan Jeannie D, Neme Santiago, Dhanireddy Shireesha, Jain Rupali

机构信息

Department of Pharmacy, University of Washington Medicine, University of Washington Medical Center - Montlake, Seattle, Washington, USA.

University of Washington School of Pharmacy, Seattle, Washington, USA.

出版信息

Clin Infect Dis. 2022 Nov 30;75(11):2049-2050. doi: 10.1093/cid/ciac588.

DOI:10.1093/cid/ciac588
PMID:35869852
Abstract
摘要

相似文献

1
Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients.帕罗韦德（奈玛特韦/利托那韦）在高危患者中的安全性和耐受性
Clin Infect Dis. 2022 Nov 30;75(11):2049-2050. doi: 10.1093/cid/ciac588.
2
Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.用于治疗新冠肺炎的奈玛特韦/利托那韦联合疗法的临床前发现与开发以及从新冠病毒变异株中吸取的经验教训。
Expert Opin Drug Discov. 2023 Jul-Dec;18(12):1301-1311. doi: 10.1080/17460441.2023.2248879. Epub 2023 Aug 23.
3
Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.化湿败毒颗粒联合奈玛特韦片/利托那韦片组合药物治疗奥密克戎（B.1.1.529）感染高风险因素患者的有效性和安全性：一项多臂、单中心、开放性、随机对照临床试验。
Phytomedicine. 2023 Nov;120:155025. doi: 10.1016/j.phymed.2023.155025. Epub 2023 Aug 16.
4
Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir.奈玛特韦通过激活 TAS2R1 苦味受体发挥作用。
Biochem Biophys Res Commun. 2023 Nov 19;682:138-140. doi: 10.1016/j.bbrc.2023.10.001. Epub 2023 Oct 2.
5
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.利托那韦增强型双蛋白酶抑制剂疗法在初治HIV-1感染患者中的疗效和安全性：2IP ANRS 127研究
J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.
6
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.与短疗程奈玛特韦和利托那韦的药物相互作用：处方医生和患者请注意。
J Clin Pharmacol. 2022 Aug;62(8):925-927. doi: 10.1002/jcph.2060. Epub 2022 May 5.
7
Optimizing the use of Paxlovid in clinical practice.优化帕罗韦德在临床实践中的使用。
Drugs Today (Barc). 2022 Nov;58(11):539-546. doi: 10.1358/dot.2022.58.11.3461265.
8
Lopinavir/ritonavir: a review of its use in the management of HIV infection.洛匹那韦/利托那韦：其在HIV感染管理中的应用综述
Drugs. 2003;63(8):769-802. doi: 10.2165/00003495-200363080-00004.
9
Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.对包括利托那韦或奈非那韦在内的治疗方案的长期反应：HIV-1感染儿童。瑞士儿科艾滋病研究小组。
Infection. 2000 Sep;28(5):287-96. doi: 10.1007/s150100070021.
10
Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.利托那韦增强型奈玛特韦（帕罗韦德）与肺癌靶向治疗及支持性护理之间的药物相互作用概述
JTO Clin Res Rep. 2023 Feb;4(2):100452. doi: 10.1016/j.jtocrr.2022.100452. Epub 2022 Dec 17.

引用本文的文献

1
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients.真实世界中，在基层医疗机构的 COVID-19 门诊患者中使用奈玛特韦/利托那韦（帕罗韦德）的安全性、耐受性和用药依从性分析。
Sci Rep. 2024 Oct 21;14(1):24750. doi: 10.1038/s41598-024-75192-9.
2
Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing.阿兹夫定对比奈玛特韦/利托那韦在奥密克戎变异株感染成年患者中的有效性和安全性：一项北京的回顾性研究。
Sci Rep. 2024 Oct 14;14(1):23974. doi: 10.1038/s41598-024-74502-5.
3
The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19.
用于治疗新冠病毒病的蛋白酶抑制剂药物组合帕罗韦德的设计、合成及作用机制
Pharmaceutics. 2024 Feb 2;16(2):217. doi: 10.3390/pharmaceutics16020217.
4
Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort).意大利托斯卡纳地区高危患者的区域队列的真实数据：COVID-19 门诊治疗的安全性和有效性（FEDERATE 队列）。
Viruses. 2023 Feb 5;15(2):438. doi: 10.3390/v15020438.
5
Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines-A Scoping Review.帕罗韦德（奈玛特韦和利托那韦）在孕妇和哺乳期妇女中的应用：当前证据与实践指南——一项范围综述
Vaccines (Basel). 2023 Jan 1;11(1):107. doi: 10.3390/vaccines11010107.
6
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A Cost-effectiveness Analysis.奈玛特韦/利托那韦处方的人群水平策略——成本效益分析
Open Forum Infect Dis. 2022 Nov 25;9(12):ofac637. doi: 10.1093/ofid/ofac637. eCollection 2022 Dec.